RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016
Published Jul 20, 2016
70 pages — Published Jul 20, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016, provides in depth analysis on RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
- The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC Beta Serine/Threon

  
Source:
Document ID
GMDHC0393TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Overview71
Therapeutics Development84
  RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Stage of Development81
  RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Therapy Area91
  RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Indication102
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Products under Development by Companies145
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Therapeutics Assessment194
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action201
  Assessment by Route of Administration211
  Assessment by Molecule Type221
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Companies Involved in Therapeutics Development238
  Almac Discovery Limited231
  ArQule, Inc.241
  AstraZeneca Plc251
  Bayer AG261
  Critical Outcome Technologies Inc.271
  Merck &Co., Inc.282
  Novartis AG301
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Drug Profiles3126
  ADC-0008830 Drug Profile311
  ALM-301 Drug Profile321
  ARQ-092 Drug Profile333
  AZD-5363 Drug Profile363
  BAY-1001931 Drug Profile391
  BAY-1125976 Drug Profile401
  COTI-2 Drug Profile418
  MK-2206 Drug Profile493
  MK-2206 + selumetinib sulfate Drug Profile521
  Small Molecules to Inhibit Akt1/2 for Oncology Drug Profile531
  trametinib dimethyl sulfoxide + uprosertib Drug Profile542
  uprosertib Drug Profile561
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Dormant Projects573
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) Featured News &Press Releases609
  Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study601
  May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment601
  Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience611
  Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers611
  Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers621
  Jan 28, 2016: ArQule Provides Update on ARQ 092621
  Dec 02, 2015: Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome631
  Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092641
  Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics651
  Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics661
  Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology661
  Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference671
  May 26, 2015: FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company's Activator of Mutant p53 Protein671
  May 11, 2015: Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2681
  Apr 27, 2015: Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2681
Appendix692
  Methodology691
  Coverage691
  Secondary Research691
  Primary Research691
  Expert Panel Validation691
  Contact Us691
  Disclaimer701

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAC-Beta-Serine-Threonine-Protein-Kinase-Protein-Kinase-Akt-2-or-Protein-Kinase-B-Beta-or-RAC-PK-Beta-or-AKT2-or-EC-2-7-11-1-Pipeline-Review-H2-2016-2088-16275>
  
APA:
Global Markets Direct - Market Research. (2016). RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/RAC-Beta-Serine-Threonine-Protein-Kinase-Protein-Kinase-Akt-2-or-Protein-Kinase-B-Beta-or-RAC-PK-Beta-or-AKT2-or-EC-2-7-11-1-Pipeline-Review-H2-2016-2088-16275>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.